4 Einträge gefunden

1. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

   1. Wei, Andrew H
   2. Panayiotidis, Panayiotis
   3. Montesinos, Pau
   4. Laribi, Kamel
   5. Ivanov, Vladimir
   6. Kim, Inho
   7. Novak, Jan

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)

   1. Wei, Andrew H
   2. Panayiotidis, Panayiotis
   3. Montesinos, Pau
   4. Laribi, Kamel
   5. Ivanov, Vladimir
   6. Kim, Inho
   7. Novak, Jan

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Author Correction:6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

   1. Wei, Andrew H
   2. Panayiotidis, Panayiotis
   3. Montesinos, Pau
   4. Laribi, Kamel
   5. Ivanov, Vladimir
   6. Kim, Inho
   7. Novak, Jan

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial

   1. Wei, Andrew Henry
   2. Montesinos, Pau
   3. Ivanov, Vladimir
   4. DiNardo, Courtney D
   5. Novak, Jan
   6. Laribi, Kamel
   7. Kim, Inho

   2020 - Forschungsinformationssystem des UKE